Abstract
Nuclear all-trans retinoic acid receptors (RARs) initiate early transcriptional events which engage pluripotent cells to differentiate into specific lineages. RAR-controlled transactivation depends mostly on agonist-induced structural transitions in RAR C-terminus (AF-2), thus bridging coactivators or corepressors to chromatin, hence controlling preinitiation complex assembly. However, the contribution of other domains of RAR to its overall transcriptional activity remains poorly defined. A proteomic characterization of nuclear proteins interacting with RAR regions distinct from the AF-2 revealed unsuspected functional properties of the RAR N-terminus. Indeed, mass spectrometry fingerprinting identified the Bromodomain-containing protein 4 (BRD4) and ALL1-fused gene from chromosome 9 (AF9/MLLT3), known to associate with and regulates the activity of Positive Transcription Elongation Factor b (P-TEFb), as novel RAR coactivators. In addition to promoter sequences, RAR binds to genomic, transcribed regions of retinoid-regulated genes, in association with RNA polymerase II and as a function of P-TEFb activity. Knockdown of either AF9 or BRD4 expression affected differentially the neural differentiation of stem cell-like P19 cells. Clusters of retinoid-regulated genes were selectively dependent on BRD4 and/or AF9 expression, which correlated with RAR association to transcribed regions. Thus RAR establishes physical and functional links with components of the elongation complex, enabling the rapid retinoid-induced induction of genes required for neuronal differentiation. Our data thereby extends the previously known RAR interactome from classical transcriptional modulators to components of the elongation machinery, and unravel a functional role of RAR in transcriptional elongation.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / pharmacology
-
Biomarkers / metabolism
-
Blotting, Western
-
Cell Cycle Proteins
-
Cell Differentiation*
-
Cell Proliferation
-
Chromatin Immunoprecipitation
-
Fluorescent Antibody Technique
-
Gene Expression Profiling
-
HeLa Cells
-
Humans
-
Immunoprecipitation
-
Nuclear Proteins / antagonists & inhibitors
-
Nuclear Proteins / genetics
-
Nuclear Proteins / metabolism*
-
Oligonucleotide Array Sequence Analysis
-
Pluripotent Stem Cells / cytology*
-
Pluripotent Stem Cells / drug effects
-
Pluripotent Stem Cells / metabolism
-
Positive Transcriptional Elongation Factor B / genetics
-
Positive Transcriptional Elongation Factor B / metabolism*
-
Promoter Regions, Genetic / genetics
-
RNA, Messenger / genetics
-
RNA, Small Interfering / genetics
-
Real-Time Polymerase Chain Reaction
-
Receptors, Retinoic Acid / genetics*
-
Receptors, Retinoic Acid / metabolism
-
Reverse Transcriptase Polymerase Chain Reaction
-
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
-
Transcription Factors / antagonists & inhibitors
-
Transcription Factors / genetics
-
Transcription Factors / metabolism*
-
Transcriptional Activation*
-
Tretinoin / pharmacology
Substances
-
Antineoplastic Agents
-
BRD4 protein, human
-
Biomarkers
-
Cell Cycle Proteins
-
MLLT3 protein, human
-
Nuclear Proteins
-
RNA, Messenger
-
RNA, Small Interfering
-
Receptors, Retinoic Acid
-
Transcription Factors
-
Tretinoin
-
Positive Transcriptional Elongation Factor B
Grants and funding
This work was funded by grants from La Ligue Nationale contre le Cancer (to PL), from European Genomic Institute for Diabetes (E.G.I.D., ANR-10-LABX-46), Contrat Plan Etat-Région “Campus Intelligent” to LH, and ANR “MULtimodal” to LH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.